Pioneering Pain-free Solutions
We leverage the power of technology to develop transformative, accurate solutions that improve quality of life.
We're on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Our Technology
Revolutionizing Portable Drug Screening Through Fingertip Sweat Analysis
Our innovative Intelligent Fingerprinting Drug Testing Solution detects commonly abused drugs via sweat from the fingertips. The system’s ease of use and portability make it a convenient solution for reliable drug screening and identification of potential misuse within the 16-24 hours before testing.
INTELLIGENT DRUG SCREENING
A Dignified Approach to Drug Screening
Our Intelligent Drug Screening system tests fingertip sweat for recent drug use, including cannabis, cocaine, opiates, and methamphetamine. Samples are collected in less than one minute and results displayed in less than ten minutes.


THE BIOSENSOR PLATFORM
A Platform for Multiple Diagnostic Tests
The biosensor platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.
News Updates

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment
Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 –

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges NEW YORK, May 15, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended